Amgen sees FY19 adjusted EPS $13.10-$14.30, consensus $14.62

Sees FY19 revenue $21.8B-$22.9B, consensus $22.94B. “Through our continued solid operating performance in 2018, we met and exceeded our long-term financial commitments. Looking to the future, we are encouraged by our long-term growth prospects driven by our portfolio of newer products, pipeline and ongoing success in international expansion,” said chairman and CEO Robert Bradway.
https://thefly.com/landingPageNews.php?id=2855417